Lyell Immunopharma, Inc.
LYEL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001806952
In the last 90 days, Lyell Immunopharma, Inc. insiders filed 0 open-market purchases and 10 sales; 87 institutions reported holding it in 13F filings for Q2 2026, worth $178.0M in total; no superinvestor holds it.
Holders of 5% or more of LYEL
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lyell Immunopharma, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13G/A | 13.90%3.25M shares | +0.90 ppfrom 13.00% | Feb 14, 20225 filings | May 15, 2026 | SEC |
| Innovative Cellular Therapeutics Holdings Ltd | 13G/A | 12.30%3.00M shares | +2.50 ppfrom 9.80% | Nov 13, 20252 filings | Jun 18, 2026 | SEC |
| Euler Fund, L.P. | 13G | 6.71%1.43M shares | New | Apr 21, 20261 filing | Apr 21, 2026 | SEC |
| Explore Investments LLC | 13G/A | 6.60%1.53M shares | +1.20 ppfrom 5.40% | Aug 19, 20252 filings | May 8, 2026 | SEC |
| Gates Frontier, LLC | 13G | 5.60%1.04M shares | New | Aug 1, 20251 filing | Aug 1, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
29 Schedule 13D and 13G filings on Lyell Immunopharma, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20264:03 PM ET | Foresite Capital Fund IV, L.P.and 6 others | 13G/A | 2.70%653.3K shares | −4.90 ppfrom 7.60%Below 5% | Jun 30, 2026 | SEC |
| Jun 18, 20264:31 PM ET | Innovative Cellular Therapeutics Holdings Ltd | 13G/A | 12.30%3.00M shares | +2.50 ppfrom 9.80% | May 18, 2026 | SEC |
| May 15, 20264:05 PM ET | ARCH Venture Fund IX, L.P.and 13 others | 13G/A | 13.90%3.25M shares | +0.90 ppfrom 13.00% | Mar 31, 2026 | SEC |
| May 11, 202611:12 AM ET | MWG Caph Ltdand 1 other | 13G/A | 4.30%1.01M shares | –Below 5% | Mar 31, 2026 | SEC |
| May 8, 20264:23 PM ET | Explore Investments LLCand 1 other | 13G/A | 6.60%1.53M shares | +1.20 ppfrom 5.40% | Mar 31, 2026 | SEC |
| Apr 21, 20269:00 AM ET | Euler Fund, L.P.and 2 others | 13G | 6.71%1.43M shares | New | Mar 6, 2026 | SEC |
| Nov 14, 20254:30 PM ET | ARCH Venture Fund IX, L.P.and 13 others | 13G/A | 13.00%2.76M shares | −0.10 ppfrom 13.10% | Sep 30, 2025 | SEC |
| Nov 14, 20254:05 PM ET | Foresite Capital Fund IV, L.P.and 6 others | 13G/A | 7.60%1.45M shares | −1.60 ppfrom 9.20% | Sep 30, 2025 | SEC |
| Nov 13, 20255:04 PM ET | Innovative Cellular Therapeutics Holdings Ltd | 13G | 9.80%1.90M shares | New | Nov 6, 2025 | SEC |
| Nov 12, 20254:57 PM ET | Newton (PTC) Ltdand 3 others | 13G/A | 3.93%754.7K shares | –Below 5% | Sep 30, 2025 | SEC |
| Aug 19, 20254:10 PM ET | Explore Investments LLCand 1 other | 13G | 5.40%1.04M shares | New | Jul 25, 2025 | SEC |
| Aug 1, 20254:15 PM ET | Gates Frontier, LLCand 1 other | 13G | 5.60%1.04M shares | New | Jul 25, 2025 | SEC |
| May 15, 20254:04 PM ET | Foresite Capital Fund IV, L.P.and 6 others | 13G/A | 9.20%27.2M shares | +2.50 ppfrom 6.70% | Mar 31, 2025 | SEC |
| Feb 14, 20254:55 PM ET | ARCH Venture Fund IX, L.P.and 7 others | 13G/A | 13.10%36.6M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20252:20 PM ET | Foresite Capital Fund IV, L.P.and 6 others | 13G/A | 6.70%19.5M shares | – | Dec 31, 2024 | SEC |
| Feb 5, 20251:23 PM ET | BlackRock, Inc. | 13G/A | 4.50%13.3M shares | –Below 5% | Dec 31, 2024 | SEC |
| Nov 12, 2024 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Nov 4, 2024 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Oct 31, 2024 | Foresite Capital Fund IV, L.P. | 13GOld format | – | – | – | SEC |
| Feb 14, 2024 | ARCH Venture Fund IX, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2024 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Jan 29, 20245:25 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Feb 13, 2023 | Foresite Capital Fund IV, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | MWG Management Limited | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Newton (PTC) Ltd | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | ARCH Venture Fund IX, L.P. | 13GOld format | – | New | – | SEC |
| Feb 11, 2022 | Foresite Capital Fund IV, L.P. | 13GOld format | – | New | – | SEC |
| Feb 10, 20224:51 PM ET | GSK plc | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Lyell Immunopharma, Inc. shares.
No Form 144 notices for Lyell Immunopharma, Inc. are on file.